These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 36854504)
1. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study. Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504 [TBL] [Abstract][Full Text] [Related]
2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117 [TBL] [Abstract][Full Text] [Related]
3. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525 [TBL] [Abstract][Full Text] [Related]
5. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945 [TBL] [Abstract][Full Text] [Related]
6. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis. Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273 [TBL] [Abstract][Full Text] [Related]
7. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Makrakis D; Talukder R; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Jang A; Barata P; Sonpavde G; Yu EY; Montgomery RB; Grivas P; Khaki AR Clin Genitourin Cancer; 2022 Oct; 20(5):e440-e452. PubMed ID: 35778337 [TBL] [Abstract][Full Text] [Related]
8. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF; Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359 [TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A; Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178 [TBL] [Abstract][Full Text] [Related]
10. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Talukder R; Makrakis D; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Jindal T; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Wright JL; Yu EY; Montgomery RB; Hsieh AC; Grivas P; Khaki AR Clin Genitourin Cancer; 2022 Dec; 20(6):558-567. PubMed ID: 36155169 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis. Huang G; Xiong H; Li S; Zhu Y; Liu H J Cancer Res Clin Oncol; 2024 Jan; 150(1):5. PubMed ID: 38170235 [TBL] [Abstract][Full Text] [Related]
12. Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study. Labidi S; Meti N; Barua R; Li M; Riromar J; Jiang DM; Fallah-Rad N; Sridhar SS; Del Rincon SV; Pezo RC; Ferrario C; Cheng S; Sacher AG; Rose AAN BMJ Open; 2024 Mar; 14(3):e081480. PubMed ID: 38553056 [TBL] [Abstract][Full Text] [Related]
13. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Tural D; Arslan C; Selcukbiricik F; Olmez OF; Erman M; Ürün Y; Erdem D; Kilickap S Clin Genitourin Cancer; 2024 Oct; 22(5):102163. PubMed ID: 39126823 [TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio. Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T Front Immunol; 2021; 12():697298. PubMed ID: 34858389 [TBL] [Abstract][Full Text] [Related]
15. First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis. Lin CT; Su PJ; Huang SY; Wu CC; Wang HJ; Cheng YT; Luo HL; Chen CH; Liu TT; Huang CC; Su YL J Immunother; 2022 Nov-Dec 01; 45(9):407-414. PubMed ID: 36121316 [TBL] [Abstract][Full Text] [Related]
16. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Rizzo A; Mollica V; Santoni M; Ricci AD; Gadaleta-Caldarola G; Montironi R; Massari F Future Oncol; 2022 Feb; 18(6):739-748. PubMed ID: 35048736 [No Abstract] [Full Text] [Related]
17. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy. Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835 [TBL] [Abstract][Full Text] [Related]
18. Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series. Jindal T; Chou J; Friedlander T; Barata PC; Koshkin VS Clin Genitourin Cancer; 2022 Apr; 20(2):189-194. PubMed ID: 34998700 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer. Yang LY; Li JR; Chen CS; Cheng CL; Hung SC; Chiu KY; Yang CK; Hsu CY; Wang SS Front Pharmacol; 2024; 15():1281654. PubMed ID: 38595923 [No Abstract] [Full Text] [Related]
20. Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer. Díaz Acedo R; Galvan Banqueri M; Artacho Criado S; Fernández Parra EM; Jiménez Galán R; Gago Sánchez AI; Marín Pozo JF; Martínez Bautista MJ Int J Clin Pharm; 2024 Apr; 46(2):382-389. PubMed ID: 38112892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]